PMID- 31920351 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220412 IS - 1178-6981 (Print) IS - 1178-6981 (Electronic) IS - 1178-6981 (Linking) VI - 11 DP - 2019 TI - Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis. PG - 799-807 LID - 10.2147/CEOR.S228400 [doi] AB - OBJECTIVE: To quantify the healthcare expenditures associated with potential oral glucocorticoid (OGC)-related adverse events (AEs) in patients with giant cell arteritis (GCA). METHODS: Patients with GCA and >/= 1 OGC prescription fill between 2009 and 2014 were identified from the MarketScan Commercial and Medicare Supplemental claims databases. Patients were stratified into four groups based on cumulative OGC dose (> 0 to 2607 to 4800 to 7200 mg) during the 1-year follow-up period; incidence of potential AEs and AE-related direct healthcare costs in USD were assessed. Association between the log of cumulative OGC dose and AE-related direct healthcare costs was evaluated, adjusting for baseline characteristics. RESULTS: Of 1602 patients with GCA included, 69% were women; the mean age was 73 years. The mean cumulative OGC dose was 5806 mg during the 1-year follow-up; most exposure occurred in the first 6 months. The proportion of patients with potential OGC-related AEs was 36.5% overall and increased as cumulative dose increased (30.7%-45.3% across dose groups). Unadjusted mean AE-related costs for patients with an AE was USD $12,818. In the multivariable model including all patients, increasing OGC dose was associated with increasing AE-related healthcare costs (cost ratio, 1.38 [95% CI, 1.16-1.64] per 1-unit increase in log of cumulative OGC dose [P < 0.001]). Mean (median)-predicted AE costs for the dose groups were USD $4389 ($2749) for > 0 to 2607 to 4800 to 7200 mg. CONCLUSION: In patients with GCA, OGC-related AEs increased with increasing cumulative OGC dose, resulting in increased healthcare costs. These results highlight the need for efficacious therapies that reduce the exposure to and potential risks associated with OGCs. CI - (c) 2019 Best et al. FAU - Best, Jennie H AU - Best JH AD - Genentech, Inc., South San Francisco, CA, USA. FAU - Kong, Amanda M AU - Kong AM AUID- ORCID: 0000-0002-6210-4185 AD - IBM Watson Health, Cambridge, MA, USA. FAU - Smith, David M AU - Smith DM AD - IBM Watson Health, Cambridge, MA, USA. FAU - Abbass, Ibrahim AU - Abbass I AD - Genentech, Inc., South San Francisco, CA, USA. FAU - Michalska, Margaret AU - Michalska M AD - Genentech, Inc., South San Francisco, CA, USA. LA - eng PT - Journal Article DEP - 20191223 PL - New Zealand TA - Clinicoecon Outcomes Res JT - ClinicoEconomics and outcomes research : CEOR JID - 101560564 PMC - PMC6934125 OTO - NOTNLM OT - adverse events OT - giant cell arteritis OT - glucocorticoid OT - healthcare expenditures COIS- JH Best, I Abbass, and M Michalska are employees and shareholders of Genentech, Inc. AM Kong and DM Smith are employees of IBM Watson Health. The authors report no other conflicts of interest in this work. EDAT- 2020/01/11 06:00 MHDA- 2020/01/11 06:01 PMCR- 2019/12/23 CRDT- 2020/01/11 06:00 PHST- 2019/08/24 00:00 [received] PHST- 2019/11/21 00:00 [accepted] PHST- 2020/01/11 06:00 [entrez] PHST- 2020/01/11 06:00 [pubmed] PHST- 2020/01/11 06:01 [medline] PHST- 2019/12/23 00:00 [pmc-release] AID - 228400 [pii] AID - 10.2147/CEOR.S228400 [doi] PST - epublish SO - Clinicoecon Outcomes Res. 2019 Dec 23;11:799-807. doi: 10.2147/CEOR.S228400. eCollection 2019.